Trial Profile
A Phase I Study of Olaparib and Low Dose Thoracic Radiotherapy for Extensive Stage Small Cell Lung Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 12 Jan 2024
Price :
$35
*
At a glance
- Drugs Olaparib (Primary)
- Indications Small cell lung cancer
- Focus Adverse reactions
- 29 Jun 2023 Planned End Date changed from 1 Jun 2023 to 1 Jun 2024.
- 29 Jun 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Jun 2024.
- 14 Sep 2022 Status changed from recruiting to active, no longer recruiting.